Results 11 to 20 of about 223,575 (250)

In situ Electrochemical Evaluation of the Interaction of dsDNA with the Proteasome Inhibitor Anticancer Drug Bortezomib. [PDF]

Molecules, 2023
Bunea MC, Enache TA, Diculescu VC.
europepmc   +3 more sources

Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors

Journal of Experimental & Clinical Cancer Research, 2022
Background Hepatocellular carcinoma (HCC) remains difficult to treat due to limited effective treatment options. While the proteasome inhibitor bortezomib has shown promising preclinical activity in HCC, clinical trials of bortezomib showed no advantage ...
Jhin Jieh Lim, Lissa Hooi, Yock Young Dan, Glenn K. Bonney, Lei Zhou, Pierce K.-H. Chow, Cheng Ean Chee, Tan Boon Toh, Edward K.-H. Chow   +8 more
doaj   +1 more source

Autophagic sequestration of SQSTM1 disrupts the aggresome formation of ubiquitinated proteins during proteasome inhibition

Cell Death and Disease, 2022
Aggresome formation is a protective cellular response to counteract proteasome dysfunction by sequestering misfolded proteins and reducing proteotoxic stress.
Chenliang Zhang, Chen Huang, Hongwei Xia, Huanji Xu, Qiulin Tang, Feng Bi   +5 more
doaj   +1 more source

Long Non-coding RNA FAM66C Promotes Prostate Cancer Metastasis via JNK-Mediated Proteasome and Lysosomal Pathway

Annals of Urologic Oncology, 2022
Purpose To identify the role of long non-coding RNA FAM66C in the metastatic progression of prostate cancer cells and its underlying mechanisms. Methods The Cancer Genome Atlas (TCGA) data was utilized to determine the relative expression of lncRNA ...
Zhenqian Qin, Kongdong Li, Jie Gu, Yimin Xie, Xuefeng Yuan   +4 more
doaj   +1 more source

Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications [PDF]

, 2012
Conjugation of ubiquitin to proteins (ubiquitylation) has emerged to be one of the most crucial post-translational modifications controlling virtually all cellular processes.
Fulda, Simone, Rajalingam, Krishnaraj, Dikic, Ivan   +2 more
core   +2 more sources

Epoxomicin, a Selective Proteasome Inhibitor, Activates AIM2 Inflammasome in Human Retinal Pigment Epithelium Cells

Antioxidants, 2022
Emerging evidence suggests that the intracellular clearance system plays a vital role in maintaining homeostasis and in regulating oxidative stress and inflammation in retinal pigment epithelium (RPE) cells. Dysfunctional proteasomes and autophagy in RPE
Iswariyaraja Sridevi Gurubaran, Maria Hytti, Kai Kaarniranta, Anu Kauppinen   +3 more
doaj   +1 more source

Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition

BMC Nephrology, 2023
Background Thrombotic microangiopathy (TMA) is a potentially organ and life-threatening condition affecting patients with multiple myeloma (MM). Cases of proteasome inhibitor-induced TMA and specifically carfilzomib-induced TMA have been rarely reported ...
Lorenzo Catanese, Katharina Link, Harald Rupprecht   +2 more
doaj   +1 more source

Selective vulnerability of neurons to acute toxicity after proteasome inhibitor treatment: Implications for oxidative stress and insolubility of newly synthesized proteins [PDF]

, 2010
Maintaining protein homeostasis is vital to cell viability, with numerous studies demonstrating a role for proteasome inhibition occurring during the aging of a variety of tissues and, presumably, contributing to the disruption of cellular homeostasis ...
Dasuri, Kalavathi, Di Blasio, Alessia, Ebenezer, Philip J., Fernandez Kim, Sun Ok, Gavilán, Elena, Keller, Jeffrey N., Uranga, Romina Maria, Zhang, Le   +7 more
core   +1 more source

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Haematologica, 2015
Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome.
Marianne Kraus, Juergen Bader, Paul P. Geurink, Emily S. Weyburne, Anne C. Mirabella, Tobias Silzle, Tamer B. Shabaneh, Wouter A. van der Linden, Gerjan de Bruin, Sarah R. Haile, Eva van Rooden, Christina Appenzeller, Nan Li, Alexei F. Kisselev, Herman Overkleeft, Christoph Driessen   +15 more
doaj   +1 more source

Effects of an anticarcinogenic Bowman-Birk protease inhibitor on purified 20S proteasome and MCF-7 breast cancer cells. [PDF]

PLoS ONE, 2014
Proteasome inhibitors have been described as an important target for cancer therapy due to their potential to regulate the ubiquitin-proteasome system in the degradation pathway of cellular proteins.
Larissa da Costa Souza, Ricardo Camargo, Marilene Demasi, Jaime Martins Santana, Cézar Martins de Sá, Sonia Maria de Freitas   +5 more
doaj   +1 more source